Back

Trading Update

11 July 2007 - Deltex Medical Group plc ('Deltex Medical' or 'Company'), the UK's leading haemodynamic monitoring company, today announces an update on progress in the six months ended 30 June 2007.

Throughout the first half of 2007 the Company made substantial progress towards delivering its goal of establishing the use of its CardioQ™ system as a standard of care in the monitoring and management of patients undergoing surgery and in critical care. Around the world, more patients than ever before are benefiting from being treated using the CardioQ™. As a result the Company has seen increased sales in each of its key markets. Sales for the six months ended 30 June 2007 are expected to be in excess of £1.9 million, compared to £1.5 million in the corresponding period in 2006.

In the USA, the world's largest medical technology market, the number of probes sold each month has increased by approximately half since the start of the year.

This growth is attributable to increasing clinical awareness of the importance of active, real time management of patients' fluids and has come both from established customers and a small number of new hospitals. The Directors believe that the strong sales growth rate in the USA in the six months ended 30 June 2007 is the result of changes in clinical practice driven by a growing belief in the benefits of fluid management guided by the CardioQ™ and does not reflect any of the potential uplift in demand associated with the Centers for Medicare and Medicaid Services 22 May decision to reimburse doctors across the USA for using the CardioQ™ on a wide range of patients.

In the Company's largest market, the UK, sales continued to grow steadily, with growth in sales of each of probes, monitors and maintenance contracts. In March, University College London Hospital announced its plan to implement routine use of the CardioQ™ as a standard of care during surgery as a core step in its redesign of surgical care: the hospital's stated goals are to improve patient outcomes and reduce average lengths of hospital stay by more than half. A growing number of other major teaching and district general hospitals across the UK are actively pursuing similar plans.

The Company is delivering strong growth in both monitor and probe sales in its International business, which is conducted mainly through distributors. The normal level of monthly probe orders from distributors is continuing to grow, with increases in standing orders from several of our key territories.

Nigel Keen, Deltex Medical's chairman, commented:
'The progress Deltex Medical has made in each of the USA, UK and International markets means that we enter the second half of 2007 with increasing momentum in all our key markets. Deltex Medical has created a clear advantage in a substantial new global market by providing proprietary technology that enables doctors to look after their patients better than ever before. The Company is strongly positioned to deliver sustained growth.'